<?xml version="1.0" encoding="UTF-8"?>
<p>Other Phase III clinical trials evaluated for COVID-19 treatment included CQ (20)/HCQ (26). These studies were endorsed by promising 
 <italic>in vitro</italic> data that suggested an impairment of viral replication by acting on endosome-mediated viral entry or later phases of viral replication.
 <xref rid="B194" ref-type="bibr">
  <sup>194</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B226" ref-type="bibr">
  <sup>226</sup>
 </xref> Both molecules have a well-studied toxicity profile being used for more than half-century as antimalarials, but in some cases can induce heart side effects.
 <xref rid="B227" ref-type="bibr">
  <sup>227</sup>
 </xref> These drugs have already been examined against at least five other viruses with good initial 
 <italic>in vitro</italic> results, but without significant effects in animal models and humans.
 <xref rid="B205" ref-type="bibr">
  <sup>205</sup>
 </xref>
</p>
